本内容遵循CC 4.0 BY-SA版权协议 简介：HEC-RAS 6.7beta4用户手册中文翻译版，定位为水利、水文与水利工程领域技术人员、研究人员及高校师生的专业参考书，面向具备一定水力学和建模基础的人员 ...

Revolution Medicines recently made history with the approval of its RAS inhibitor Rasonque for advanced pancreatic cancer. But behind RevMed is an entire field of biotechs working to broaden the reach ...

The U.S. Food and Drug Administration (FDA) has approved daraxonrasib, an oral multi-selective RAS(ON) inhibitor, for adults with metastatic pancreatic adenocarcinoma who have received at least one ...

The FDA approved daraxonrasib, the first targeted therapy for metastatic pancreatic adenocarcinoma, citing a survival benefit vs chemotherapy. The FDA approved daraxonrasib (Rasonque; Revolution ...

The FDA has approved the first RAS-targeted therapy for metastatic pancreatic cancer, offering a new treatment option for patients with previously treated disease. Daraxonrasib (Rasonque, Revolution ...

Unmanned Surface Vessel Division 12 (Sea Hunter) and 13 (Sea Hunter) conduct unit level training underway in San Diego Bay, California, May 1, 2025. US Navy photo The Navy’s portfolio acquisition ...

On each fresh manual launch, the GUI automatically uploads only the allowlisted project files using GitHub CLI, then replaces its own process with a restarted copy. The old GUI closes because ...

b RAS G12, G13 or Q61 mut or no RAS mut identified. This is an ASCO Meeting Abstract from the 2026 ASCO Annual Meeting II. This abstract does not include a full text component.

At the moment, RevMed remains keenly focused on its mission to bring daraxonrasib to the masses and continue developing new medicines that target RAS. (Darren Incorvaia) This year’s meeting of the ...

Current therapies offer limited benefit for patients with previously treated metastatic pancreatic ductal adenocarcinoma (mPDAC). Aberrant activation of the RAS pathway is the key driver of PDAC, with ...

The targeted RAS inhibitor daraxonrasib was found to be safe and showed signs of efficacy in a phase 1/2 first-in-human trial in patients with previously treated, RAS-mutant, metastatic pancreatic ...